Dyax Launches Hereditary Angioedema Genetic Counseling Program To Educate Patients And Family Members About Disease And Inheritance

Dyax Corp. (NASDAQ: DYAX) the manufacturer of KALBITOR ® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older, has announced the launch of its HAE genetic counseling program. The program, which is available to all members of the HAE community, provides diagnosed HAE patients and their family members with a free counseling session.

“We are pleased to bring this important resource to the HAE community”, said Gustav Christensen, President and Chief Executive Officer of Dyax. “As leaders in this community, we see the provision of these types of resources and support as an important way to help meet the needs of HAE patients”.

Dyax’s genetic counseling program provides eligible HAE patients with access to board-certified and state licensed genetic counselors that are available nationally for phone, internet or in-person counseling sessions. The service includes an overview of the condition, family planning counseling and patient education and resources.

"The HAEA supports all efforts to help HAE patients”, said Janet Long, Executive Vice President, US Hereditary Angioedema Association, "and we greatly appreciate Dyax’s efforts in this area."

Patients can enroll in the program by calling 855-HAE Hope (855-423-4674) or by visiting http://www.haehope.com/haegeneticcounseling. The HAE genetic counseling program is just part of a suite of services that Dyax provides to HAE patients. To learn more about other Dyax programs and services, please contact 855-423-4674 or visit www.dyax.com.

About HAE

Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect 1 in 10,000 to 1 in 50,000 individuals. Learn more at www.HAEHope.com.

About KALBITOR® (ecallantide)

KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by Dyax, is the first subcutaneous treatment available in the U.S. for treating acute HAE attacks.

If you liked this article you might like

Shire to Acquire Biopharma Company Baxalta in $32B Deal

The Nominees for Best Biopharma CEO of 2015 Are...

3 Drugs Stocks Moving The Industry Upward

Dyax (DYAX) Moving On Heavy Volume In The Pre-Market Hours

OPEC Begins Meeting Today, Saudis May Cut Oil Production